How Does CAR-T Therapy’s Efficacy Translate to Clinical Value for Hong Kong Patients With Refractory Hematological Malignancies, and How Can Optimized Manufacturing Help Close the Current Access Gap?. J. Med. Life Sci. 2026, 2 (1), 53-70. https://doi.org/10.71222/dt007s28.